Location History:
- Chiba, JP (2015 - 2016)
- Kashiwa, JP (2015 - 2020)
Company Filing History:
9 out of 11 
3 out of 1,287 
2 out of 340 
Years Active: 2015-2020
Title: Innovations of Kanehisa Kojoh: Pioneering New Antibodies for Medical Applications
Introduction
Kanehisa Kojoh is an influential inventor based in Kashiwa, Japan. With a remarkable portfolio of nine patents, his contributions to the field of biotechnology, particularly in antibody development, have significant implications for medical therapies.
Latest Patents
Kojoh’s recent inventions demonstrate his focus on addressing critical health challenges. His patent for an "Anti-human CD69 antibody, and use thereof for medical purposes" presents an antibody that selectively binds to human CD69, showcasing properties that suppress allergic inflammation and exhibit cross-reactivity with mouse CD69. This antibody not only has therapeutic potential for human conditions but possesses a high binding affinity, making it a promising candidate for treating various allergic responses.
Another notable patent involves a "Human antibody against aggrecanase-type ADAMTS species for therapeutics of aggrecanase-related diseases." This innovation highlights an antibody specifically engineered to bind to human aggrecanase, effectively inhibiting its enzymatic activity. By targeting ADAMTS4 and ADAMTS5, this invention could pave the way for effective prophylaxis or treatment of arthritis progression, demonstrating significant therapeutic potential.
Career Highlights
Kojoh has had a vibrant career, contributing his expertise to companies such as Genefrontier Corporation and Keio University. His work at these institutions has enabled him to collaborate on groundbreaking research and innovate solutions that address health-related issues through antibody therapies.
Collaborations
Throughout his career, Kojoh has partnered with notable colleagues including Shizue Katoh and Akira Miyakoshi. These collaborations have fostered a rich environment of innovation and have undoubtedly enhanced the scope and impact of his work.
Conclusion
Kanehisa Kojoh's innovations signify a remarkable blend of scientific inquiry and practical application in the field of biomedicine. His recent patents not only highlight his role as a leading inventor but also underscore the potential for his work to contribute significantly to future medical interventions. As the demand for innovative therapies grows, Kojoh's advancements in antibody technology will undoubtedly play a pivotal role in shaping the future of healthcare.